Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | LIPE | Q05469 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10642006 | 0.89 | LMNA (0.58) | SMN1; SMN2LMNAFFAR1ALDH1A1LIPE | |
| SCHEMBL10584608 | 0.85 | FFAR1 (0.68) | SMN1; SMN2LMNAFFAR1ALDH1A1LIPE | |
| SCHEMBL16726906 | 0.85 | L3MBTL1 (0.49) | SMN1; SMN2LMNAFFAR1ALDH1A1LIPE | |
| SCHEMBL11349350 | 0.85 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAFFAR1ALDH1A1LIPE | |
| SCHEMBL10643790 | 0.84 | LMNA (0.60) | SMN1; SMN2LMNAFFAR1ALDH1A1LIPE | |
| SCHEMBL9362359 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNAFFAR1ALDH1A1LIPE | |
| SCHEMBL14773341 | 0.84 | KMT2A (0.68) | SMN1; SMN2LMNAFFAR1ALDH1A1LIPE | |
| SCHEMBL2622341 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAFFAR1ALDH1A1LIPE | |
| SCHEMBL9366059 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAFFAR1ALDH1A1LIPE | |
| SCHEMBL10642280 | 0.82 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAFFAR1ALDH1A1LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | KOYUNCU EMRE (US) | 2015-05-21 | — | — | US | disclosed |
| EP-2581081-A2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2572712-A2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2012139028-A2 | ANTI-VIRAL COMBINATION THERAPY | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-10-11 | — | — | WO | disclosed |
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| WO-2009023059-A2 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2009-02-19 | — | — | WO | disclosed |
| EP-0000483-B1 | TRIFLUOROMETHYL PYRIDINYL(OXY/THIO)PHENOXY PROPANOIC ACIDS AND PROPANOLS AND DERIVATIVES THEREOF | THE DOW CHEMICAL COMPANY (US) | 1981-10-14 | — | — | EP | disclosed |
| EP-0000483-A1 | Trifluoromethyl pyridinyl(oxy/thio)phenoxy propanoic acids and propanols and derivatives thereof | THE DOW CHEMICAL COMPANY (US) | 1979-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | SMN1; SMN2 2585/4885LMNA 4191/4885FFAR1 2747/4885 |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | SMN1; SMN2 2585/4885LMNA 4191/4885FFAR1 2747/4885 |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | HAVCR2, MAVS, ZC3HAV1 | SMN1; SMN2 4448/4885LMNA 4540/4885FFAR1 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.